RALEIGH, N.C., May 02, 2017 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (PRA) (NASDAQ:PRAH) is pleased to announce that it was once again recognized as the Clinical Research Company of the Year. PRA received the award at the PharmaTimes Clinical Researcher of the Year Americas ceremony in Seattle, Washington. This is the fifth consecutive year that PRA has received this prestigious recognition.
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/3ca5375f-437a-4de8-9615-629592b52a5c
“We are extremely proud of this accomplishment,” said Michael Brooks, Executive Vice President, Product Registration, Americas. “This award is a testament to the incredible talent, professionalism and dedication that PRA employees bring to their clinical development work and their desire to help others.”
PRA was well represented in the competition, with 40 finalists in five different categories. Individual gold award recipients from PRA include:
- Strategic Partnership Team (PRA and BioMarin): Michael Bodmann, Tony Eckhoff and Danielle Libero (PRA participants)
- Company Team: Jo-Zahn Baxter, Jeff Janotka, Valerie Kerr, LaTheena Thomas and Jennifer Vance
Organized by PharmaTimes, the Clinical Researcher of the Year competition is considered a key barometer of quality standards in the contract research organization (CRO) industry. The multi-stage competition is organized by an independent executive steering committee drawn from senior industry leaders from big and small pharma, leading CROs, and professional membership associations.
ABOUT PRA HEALTH SCIENCES
PRA (NASDAQ:PRAH) is one of the world’s leading global CROs by revenue, providing outsourced clinical development services to the biotechnology and pharmaceutical industries. PRA’s global clinical development platform includes more than 70 offices across North America, Europe, Asia, Latin America, South Africa, Australia and the Middle East and over 13,300 employees worldwide. Since 2000, PRA has performed approximately 3,500 clinical trials worldwide. In addition, PRA has participated in the pivotal or supportive trials that led to U.S. Food and Drug Administration or international regulatory approval of more than 70 drugs. To learn more about PRA, please visit www.prahs.com.
INQUIRIES: Christine Rogers, Manager – Public Relations, Corporate Communications
EMAIL: email@example.com PHONE: +1 919.786.8463
INVESTOR INQUIRIES: InvestorRelations@prahs.com
PRA Health Sciences, Inc.